Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

PURPOSE: Cisplatin is synergistic with vinorelbine and the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib, and has anti-neoplastic activity in TNBC and BRCA mutation-associated breast cancer. This phase I study assessed veliparib with cisplatin and vinorelbine. PATIENTS AND METHODS: A 3+3 do...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Rodler, Eve T., Kurland, Brenda F., Griffin, Melissa, Gralow, Julie R., Porter, Peggy, Yeh, Rosa F., Gadi, Vijayakrishna K., Guenthoer, Jamie, Beumer, Jan H., Korde, Larissa, Strychor, Sandra, Kiesel, Brian F., Linden, Hannah M., Thompson, John A., Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, Specht, Jennifer M.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911292/
https://ncbi.nlm.nih.gov/pubmed/26801247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares